San Francisco, CA10 Active Studies

Brain Cancer Clinical Trials in San Francisco, CA

Find 10 actively recruiting brain cancer clinical trials in San Francisco, CA. Connect with local research sites and explore new treatment options.

10
Active Trials
8
Sponsors
3,553
Enrolling

Recruiting Brain Cancer Studies in San Francisco

RecruitingSan Francisco, CANCT03970447

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple...

1,280 participants
Global Coalition for Adaptive Research
View Study Details
RecruitingSan Francisco, CANCT05902169

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier prope...

560 participants
CarThera
View Study Details
RecruitingSan Francisco, CANCT05580562

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC...

450 participants
Chimerix
View Study Details
RecruitingSan Francisco, CANCT05566795

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in ...

400 participants
Day One Biopharmaceuticals, Inc.
View Study Details
RecruitingSan Francisco, CANCT05009992

Combination Therapy for the Treatment of Diffuse Midline Gliomas

This phase II trial determines if the combination of ONC201 with different drugs, panobinostat or paxalisib, is effective for treating participants with diffuse midline gliomas (DMGs). Despite years o...

360 participants
University of California, San Francisco
View Study Details
RecruitingSan Francisco, CANCT05708352

A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment

This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Di...

170 participants
Cedars-Sinai Medical Center
View Study Details
RecruitingSan Francisco, CANCT04775485

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying ...

141 participants
Day One Biopharmaceuticals, Inc.
View Study Details
RecruitingSan Francisco, CANCT06069726

A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial

This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden....

80 participants
Duke University
View Study Details
RecruitingSan Francisco, CANCT06504381

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patie...

70 participants
University of California, San Francisco
View Study Details
RecruitingSan Francisco, CANCT06478212

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

The objective of this study is to determine the safety and tolerability of vorasidenib in combination with temozolomide (TMZ) and to establish the recommended combination dose (RCD) of vorasidenib. Th...

42 participants
Institut de Recherches Internationales Servier
View Study Details

About Brain Cancer Clinical Trials in San Francisco

Brain cancer includes tumors that originate in the brain (primary) or spread from other areas (metastatic). Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Treatment typically combines surgery, radiation, and chemotherapy, with immunotherapy trials underway.

There are currently 10 brain cancer clinical trials recruiting participants in San Francisco, CA. These studies are seeking a combined 3,553 participants. Research is being sponsored by Global Coalition for Adaptive Research, CarThera, Chimerix and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Brain Cancer Clinical Trials in San Francisco — FAQ

Are there brain cancer clinical trials in San Francisco?

Yes, there are 10 brain cancer clinical trials currently recruiting in San Francisco, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in San Francisco?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the San Francisco research site will contact you about next steps.

Are clinical trials in San Francisco free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many San Francisco studies also compensate for your time and travel.

What brain cancer treatments are being tested?

The 10 active trials in San Francisco are testing new therapies including novel drugs, biologics, and treatment approaches for brain cancer.

Data updated March 2, 2026 from ClinicalTrials.gov